<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551419</url>
  </required_header>
  <id_info>
    <org_study_id>2015-509</org_study_id>
    <nct_id>NCT02551419</nct_id>
  </id_info>
  <brief_title>Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET (Positron Emission Tomography)</brief_title>
  <acronym>BENEFIC</acronym>
  <official_title>Effect of a Ketogenic Supplement on Brain Energy Metabolism Measured by Neuroimaging in Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A six month, placebo-controlled, parallel group project in which MCI participants will
      receive 30 g/day of a custom-made MCT-based ketogenic supplement or a matching placebo.
      Uptake of both the brain's fuels - ketones (as 11C-AcAc) and glucose (as FDG) - both before
      and after the intervention will be assessed by PET (position emission tomography) imaging, as
      well as fMRI, diffusion MRI and cognition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global ketone (11C-AcAc) uptake in grey matter</measure>
    <time_frame>Baseline and 6 months of intervention</time_frame>
    <description>The change in brain ketone uptake will be quantified by PET and expressed as cerebral metabolic rate of AcAc (CMR-A)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in global brain FDG uptake in grey matter (CMR-G)</measure>
    <time_frame>Baseline and 6 months of intervention</time_frame>
    <description>The change in brain glucose uptake will be quantified by PET and expressed as cerebral metabolic rate of glucose (CMR-G)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in regional CMR-A</measure>
    <time_frame>Baseline and 6 months of intervention</time_frame>
    <description>The change in brain ketone uptake will be quantified by PET in different regions of the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in regional CMR-G in the temporal and parietal cortex</measure>
    <time_frame>Baseline and 6 months of intervention</time_frame>
    <description>The change in brain glucose uptake will be quantified by PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MRI-based (fMRI, diffusion MRI) parameters</measure>
    <time_frame>Baseline and 6 months of intervention</time_frame>
    <description>Measure changes in brain blood flow by ASL, brain activation by rs-fMRI, integrity of brain white matter tracts by dMRI, and regional brain volumes by vMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive status</measure>
    <time_frame>Baseline and 6 months of intervention</time_frame>
    <description>cognitive status assessed by the following cognitive test: verbal fluency (D-KEFS), Boston Naming Test, Trail Making test (D-KEFS), Stroop Color and Word Test (D-KEFS), Digit Span (WAIS III), Digit Symbol (WAIS III), Brief Visuospatial Memory Test-revised, 16-item free/cued word learning (Buschke and Grober test)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>ketogenic drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ketogenic drink</intervention_name>
    <description>6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.</description>
    <arm_group_label>ketogenic drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>6 months' supplementation with the palcebodrink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MoCA score ≥26/30 and good physical autonomy

        Exclusion Criteria:

          -  diseases or psychiatric disorders that could interfere with participation; fasting
             plasma glucose ≥6.0 mM; substance abuse; already supplementing with coconut oil or
             MCT; nut allergy; visual or hearing impairment impeding comprehension;
             non-English/French speaking; institutionalization; intention of moving out of the
             immediate area within 1 year; participation in another intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Cunnane, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mélanie Fortier, M.Sc.</last_name>
    <phone>819-780-2220</phone>
    <phone_ext>45252</phone_ext>
    <email>melanie.fortier2@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Castellano, Ph.D.</last_name>
    <phone>819-780-2220</phone>
    <phone_ext>45623</phone_ext>
    <email>Alexandre.Castellano@USherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Center on Aging</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Fortier, M.Sc.</last_name>
      <phone>819-780-2220</phone>
      <phone_ext>45252</phone_ext>
      <email>melanie.fortier2@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Castellano, Ph.D.</last_name>
      <phone>819-780-2220</phone>
      <phone_ext>45623</phone_ext>
      <email>Alexandre.Castellano@USherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Cunnane, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Castellano CA, Nugent S, Paquet N, Tremblay S, Bocti C, Lacombe G, Imbeault H, Turcotte É, Fulop T, Cunnane SC. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J Alzheimers Dis. 2015;43(4):1343-53. doi: 10.3233/JAD-141074.</citation>
    <PMID>25147107</PMID>
  </reference>
  <reference>
    <citation>Nugent S, Castellano CA, Goffaux P, Whittingstall K, Lepage M, Paquet N, Bocti C, Fulop T, Cunnane SC. Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1315-21. doi: 10.1152/ajpendo.00067.2014. Epub 2014 Apr 15.</citation>
    <PMID>24735889</PMID>
  </reference>
  <reference>
    <citation>Nugent S, Tremblay S, Chen KW, Ayutyanont N, Roontiva A, Castellano CA, Fortier M, Roy M, Courchesne-Loyer A, Bocti C, Lepage M, Turcotte E, Fulop T, Reiman EM, Cunnane SC. Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol Aging. 2014 Jun;35(6):1386-95. doi: 10.1016/j.neurobiolaging.2013.11.027. Epub 2013 Dec 1.</citation>
    <PMID>24388785</PMID>
  </reference>
  <reference>
    <citation>Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S, Castellano CA, Cunnane SC. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition. 2013 Apr;29(4):635-40. doi: 10.1016/j.nut.2012.09.009. Epub 2012 Dec 28.</citation>
    <PMID>23274095</PMID>
  </reference>
  <reference>
    <citation>Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N, Begdouri H, Bentourkia M, Turcotte E, Allard M, Barberger-Gateau P, Fulop T, Rapoport SI. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition. 2011 Jan;27(1):3-20. doi: 10.1016/j.nut.2010.07.021. Epub 2010 Oct 29. Review.</citation>
    <PMID>21035308</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild cognitive impairment</keyword>
  <keyword>ketones</keyword>
  <keyword>medium chain triglycerides</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>cognition</keyword>
  <keyword>brain</keyword>
  <keyword>neuroimaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

